Featured Press Releases
BIO, Biocom, and California Life Sciences Sue to…
Complaint argues HHS and CMS exceeded statutory authority; rule puts patient access, investment in future innovation, and America’s long-term biotechnology leadership at risk.WASHINGTON, DC & SAN DIEGO, CA & SAN FRANCISCO, CA - The…
U.S. Bioscience Industry Powers Over $3 Trillion…
WASHINGTON, DC (October 28, 2026) – Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact…
BIO Statement on Proposed Rule to Implement…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the proposed Outbound Investment Security Program (OISP) rule:"The Administration is correct that…
Biotechnology Innovation Organization
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2026 All Rights Reserved